Annovis Bio Secures $3.4 Million in Registered Direct Offering to Advance Neurodegenerative Disease Therapies
Annovis Bio has raised $3.4 million through a registered direct offering to fund development of treatments for Alzheimer's and Parkinson's diseases, providing crucial capital for advancing late-stage clinical programs targeting neurodegeneration.
Annovis Bio Inc. (NYSE: ANVS) has secured $3.4 million in funding through a registered direct offering of common stock, providing essential capital for the company's ongoing development of therapies for neurodegenerative diseases. The late-stage clinical drug platform company entered definitive agreements for the sale of 1,670,732 shares at $2.05 per share, matching the company's closing price on October 24. This financing round represents a significant milestone for Annovis as it advances its pipeline targeting Alzheimer's disease and Parkinson's disease.
The offering was led by H.C. Wainwright & Co. as exclusive placement agent, demonstrating institutional confidence in Annovis's clinical development strategy. Notably, the financing attracted participation from key company leadership, including Chairman Michael Hoffman and CEO Dr. Maria Maccecchini, signaling strong internal commitment to the company's mission. The transaction is expected to close on or about October 28, 2025, with proceeds designated for working capital and general corporate purposes to support ongoing research and development activities.
This funding comes at a critical juncture for Annovis Bio as the company continues developing innovative therapies aimed at addressing neurodegeneration in Alzheimer's and Parkinson's diseases. The capital infusion will support the company's commitment to improving patient outcomes and quality of life through novel treatment approaches. For additional details about the offering, investors can review the full press release available at https://ibn.fm/d1q9Q.
The neurodegenerative disease treatment market represents one of the most challenging and important areas in pharmaceutical development, with Alzheimer's disease affecting approximately 6.7 million Americans and Parkinson's disease impacting nearly one million people in the United States. Annovis Bio's approach to targeting the underlying mechanisms of neurodegeneration positions the company at the forefront of addressing these devastating conditions. The successful completion of this financing round underscores investor confidence in the company's scientific approach and clinical development strategy.
For ongoing updates and news related to Annovis Bio, the company maintains an accessible newsroom at https://ibn.fm/ANVS. The company's corporate website at https://www.annovisbio.com provides comprehensive information about their research programs and therapeutic candidates. This funding round represents a strategic step forward in advancing treatments that could potentially transform care for millions of patients suffering from neurodegenerative diseases worldwide.